Scholar Rock Holding (SRRK) Enterprise Value (2017 - 2026)
Scholar Rock Holding's quarterly Enterprise Value came in at -$479.9 million in Q1 2026, down 31.72% year-on-year from -$702.9 million in Q1 2025, and down 30.57% quarter-over-quarter from -$367.6 million in Q4 2025.
Scholar Rock Holding has reported Enterprise Value for 10 years, with the latest figure at -$479.9 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 31.72% year-over-year to -$479.9 million; the trailing twelve-month figure through Mar 2026 stood at -$479.9 million (down 31.72% YoY), and the FY2025 full-year result was -$367.6 million, up 15.94% from the prior year.
- Enterprise Value for Q1 2026 stood at -$479.9 million, down from -$367.6 million in the prior quarter.
- The five-year high for Enterprise Value was -$139.1 million in Q3 2024, with the low at -$479.9 million in Q1 2026.
- Average Enterprise Value over 5 years is -$302.6 million, with a median of -$295.0 million recorded in 2025.
- Year-over-year, Enterprise Value soared 36.39% in 2024 and plunged 165.8% in 2025.
- Tracing SRRK's Enterprise Value over 5 years: stood at -$315.4 million in 2022, then grew by 11.23% to -$279.9 million in 2023, then sank by 56.21% to -$437.3 million in 2024, then rose by 15.94% to -$367.6 million in 2025, then tumbled by 30.57% to -$479.9 million in 2026.
- The last three Enterprise Value figures came in at -$479.9 million (Q1 2026), -$367.6 million (Q4 2025), and -$369.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | -479.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -479.94 Mn |
| Dec 31, 2025 | -367.56 Mn |
| Sep 30, 2025 | -369.63 Mn |
| Jun 30, 2025 | -295.01 Mn |
| Mar 31, 2025 | -364.38 Mn |
| Dec 31, 2024 | -437.28 Mn |
| Sep 30, 2024 | -139.07 Mn |
| Jun 30, 2024 | -190.49 Mn |
| Mar 31, 2024 | -238.43 Mn |
| Dec 31, 2023 | -279.94 Mn |
| Sep 30, 2023 | -218.64 Mn |
| Jun 30, 2023 | -248.73 Mn |
| Mar 31, 2023 | -275.28 Mn |
| Dec 31, 2022 | -315.36 Mn |
| Sep 30, 2022 | -343.66 Mn |
| Jun 30, 2022 | -370.69 Mn |
| Mar 31, 2022 | -210.21 Mn |
| Dec 31, 2021 | -252.99 Mn |
| Sep 30, 2021 | -246.44 Mn |
| Jun 30, 2021 | -282.22 Mn |
| Mar 31, 2021 | -314.69 Mn |
| Dec 31, 2020 | -341.03 Mn |
| Sep 30, 2020 | -116.26 Mn |
| Jun 30, 2020 | -141.18 Mn |
| Mar 31, 2020 | -160.65 Mn |
| Dec 31, 2019 | -157.45 Mn |
| Sep 30, 2019 | -176.08 Mn |
| Jun 30, 2019 | -185.13 Mn |
| Mar 31, 2019 | -159.67 Mn |
| Dec 31, 2018 | -175.65 Mn |
| Sep 30, 2018 | -103.99 Mn |
| Jun 30, 2018 | -115.06 Mn |
| Dec 31, 2017 | -57.96 Mn |